Navigation Links
Experimental Chemical Helps Blind Mice See
Date:7/25/2012

WEDNESDAY, July 25 (HealthDay News) -- A novel chemical temporarily restored some vision to blind mice, and this success may eventually lead to a treatment to help people with degenerative blindness see again, according to a new study.

Those who could benefit include people with retinitis pigmentosa and age-related macular degeneration (AMD). Retinitis pigmentosa is a genetic disease that is the most common inherited form of blindness, while AMD is the most common cause of acquired blindness in the developed world.

In both diseases, light sensitive cells in the retina called rods and cones die and leave the eye without functioning photoreceptors.

The mice used in this study had genetic mutations that made their rods and cones die within months of birth. Injections of the chemical AAQ into the eyes of the blind mice temporarily restored their light sensitivity, according to the study published in the July 26 issue of the journal Neuron.

AAQ makes the remaining, normally "blind" cells in the retina sensitive to light, lead researcher Richard Kramer, a professor of molecular and cell biology at the University of California, Berkeley, explained in a university news release.

This approach "offers real hope to patients with retinal degeneration," study co-author Dr. Russell Van Gelder, chair of the ophthalmology department at the University of Washington in Seattle, said in the news release.

"We still need to show that these compounds are safe and will work in people the way they work in mice, but these results demonstrate that this class of compound restores light sensitivity to retinas blind from genetic disease," he added.

The researchers noted that the chemical eventually wears off, which may make it a safer alternative to other experimental methods for restoring sight, such as gene or stem cell therapies, which permanently change the retina. Chemical treatment is also less invasive than implanting light-sensitive chips in the eye, the researchers said.

"The advantage of this approach is that it is a simple chemical, which means that you can change the dosage, you can use it in combination with other therapies, or you can discontinue the therapy if you don't like the results. As improved chemicals become available, you could offer them to patients. You can't do that when you surgically implant a chip or after you genetically modify somebody," Kramer explained.

However, experts note that while studies involving animals can be useful, they frequently fail to produce similar results in humans.

The research was supported by the U.S. National Institutes of Health's National Eye Institute and Research to Prevent Blindness.

More information

The U.S. National Eye Institute has more about age-related macular degeneration.

-- Robert Preidt

SOURCE: University of California, Berkeley, news release, July 25, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental drug may extend therapeutic window for stroke
2. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
3. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
4. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
5. Experimental drug improves muscle strength among male cancer patients
6. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
7. Experimental Drug Eases Autistic Behaviors in Mice
8. Experimental Gel May Help Those With Advanced Parkinsons
9. Experimental Pill for Multiple Sclerosis Shows Promise
10. Experimental Chemo Combo for Colon Cancer Disappoints
11. American Chemical Societys highest honor to Peter Stang
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a ... Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with ... help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016   AlloSource , one ... bone, skin and soft-tissue allografts for use in ... Process Manager, for being named to the Board ... Quality Award by the Commerce Department,s National Institute ... commitment to process excellence. The Baldrige Award is ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
(Date:12/6/2016)... 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... kinase medicines for patients with genomically defined diseases, today ... of $125,000,000 million in shares of its common stock. ... a 30-day option to purchase up to an additional ... in connection with the public offering. All shares of ...
Breaking Medicine Technology: